Under Momentum Swing, the report notes a Buy call on Fortis Nov futures where the first target was achieved and profit booked at 744, with a further target of 760.
Read this note →Fortis Healthcare Limited
NSE FORTIS BSE 532843 INE061F01013
0 filings · 0 analysed
774.55
-1.49%
over 1 month
-
Under Momentum Swing, the report notes a Buy call on Fortis Nov futures where the first target was achieved and profit booked at 744, with a further target of 760.
-
The report gives a technical SELL call on Fortis (CMP Rs 757) with a stoploss of Rs 779 and targets of Rs 740 and Rs 728.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| Mirae Asset Sharekhan | 27 Oct 2026, 16:27 | long | 734.70 | 744.00 | 759.50 | 200% | hit |
| Sharekhan (Mirae Asset Sharekhan) | 12 Oct 2026, 16:35 | short | 757.25 | 740.00 | 712.90 | 200% | hit |
| JM Financial | 13 Nov 2025, 08:08 | long | 951.99 | 1,090.00 | 766.90 | -100% | open by 2026-11-13 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report gives a technical SELL call on Fortis (CMP Rs 757) with a stoploss of Rs 779 and targets of Rs 740 and Rs 728.
Read this note →The report expects Fortis to post 7% YoY EBITDA growth but a 3% YoY PAT decline due to ramp-up of recently acquired facilities, with plans to add 400 beds.
Read this note →The note says Fortis has signed an agreement to provide healthcare services at a 400+ bed super speciality hospital in Delhi, expected to commence operations in 3-4 years.
Read this note →The note says Fortis delivered strong 2QFY26 results with revenue/EBITDA/PAT up 17%/28%/82% YoY and EBITDA margin of 23.9% (up 199bps YoY), and that margins should improve as more assets mature and EBITDA per occupied bed rises from INR 5mn in FY25 to INR 7mn in FY28, but after valuation multiples expanded to 28x FY27 EV/EBITDA versus a 5-year average of 21x, the analysts downgrade to ADD with an SOTP-based target of INR 1,090 (12.4% upside from INR 969) versus a previous target of INR 1,029.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief